PD-L1 Expression in Patients with Non-small Cell Lung Cancer

6Citations
Citations of this article
8Readers
Mendeley users who have this article in their library.

Abstract

Aim: The aim of this study was to evaluate whether irradiation induces the expression of tumor programed cell death ligand 1 (PD-L1) in patients with non-small cell lung cancer (NSCLC). Patients and Methods: Seventeen patients with NSCLC who received chemoradiotherapy and underwent tumor resection and six patients whose pre-treatment biopsy specimens were available, were analyzed by immuno -histochemistry for PD-L1 expression between September 2011 and June 2016 at the Institute of Biomedical Research and Innovation Hospital. Results: Among six patients for which pre-irradiation biopsy samples were available, the H-score for PD-L1 was reduced after irradiation following staining with two different antibody clones (SP28-8 and SP142). A PD-L1 H-score >5 with SP28-8 antibody (hazard ratio=6.46; 95% confidence interval=1.209-34.53; p=0.029) was a significant negative factor for duration of progression-free survival after curative operation or chemoradiation. Conclusion: We showed that tumor PD-L1 expression decreased in patients with NSCLC who received chemoradiotherapy and radiation resistance might be due to pre-treatment PD-L1 expression.

Cite

CITATION STYLE

APA

Masago, K., Fujita, S., Hata, A., Okuda, C., Kaji, R., Katakami, N., & Hirata, Y. (2017). PD-L1 Expression in Patients with Non-small Cell Lung Cancer. Anticancer Research, 37(5), 2269–2274. https://doi.org/10.21873/anticanres.11564

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free